Proscia provides the Concentriq enterprise digital pathology platform, which includes three purpose-built products: Concentriq LS for life sciences R&D, Concentriq AP for diagnostic lab digitization, and Concentriq AP-Dx, which is FDA-cleared for primary diagnosis. The platform supports seamless interoperability and AI integration, helping academic medical centers, health systems, commercial labs, and life sciences organizations accelerate research and diagnostic workflows. Proscia also offers an AI Portfolio for building and deploying AI solutions, and Proscia Aperture for real-time patient insights. The platform is used daily by over 12,000 pathologists and scientists, including 16 of the top 20 pharma companies. Proscia has been recognized as Best in KLAS in Europe and top-scored in the US, and has received funding to advance AI-driven pathology.